Singapore, May 14 -- In a significant step towards strengthening India's advanced biotechnology and cell therapy system, the Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India, has entered into an agreement with Helix Cell Therapeutics, for a project titled "Fabrication and Phase I Clinical Trial of Novel Dual Targeting Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma".

The project is being implemented under the India-Singapore collaborative framework in partnership with Singapore-based Biocell Innovations.

This project focuses on developing an advanced dual-targeting CAR-T cell therapy for multiple myeloma. Multiple myeloma is a debilitating and currently inc...